The long-term efficacy of endoscopic treatment of pancreas divisum is controversial. This review focuses on recent literature on the role of endoscopic ultrasonography (EUS) as effective clinical support in the diagnosis and management of pancreas divisum. A challenging case study in a patient with pancreas divisum affected by recurrent acute pancreatitis and chronic pain is also reported. Our methodology was developed from a search strategy based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. A comprehensive electronic search across multiple databases, including Medline/PubMed, EMBASE, Medline/Metacrawler and the Cochrane Library, to identify relevant publications for this systematic review was conducted. A total of 308 articles were found. According to EMBASE grouping criteria, 31 articles were considered major clinical studies and were analysed, reporting for each study the relevant clinical features. In the majority of studies examined, EUS proved useful in diagnosing a pancreatic divisum. The EUS diagnostic yield was reported to have a sensitivity ranging from 51% to 95% and high diagnostic accuracy up to 97%. EUS has shown high sensitivity and specificity in diagnosing pancreas divisum. Studies indicate that EUS can achieve sensitivity rates ranging from 80% to 100% and specificity rates around 97% to 100% for detecting pancreas divisum. Based on these figures, EUS is the most reliable imaging system in terms of diagnostic capability compared with other imaging systems.
Driven by shifting cultural paradigms, increasing health consciousness, and evolving regulatory environments, the global market for non-alcoholic and low-alcohol (NoLo) beverages is experiencing rapid expansion. This review provides a comprehensive synthesis of the NoLo beverage sector by integrating public health implications, regulatory frameworks, technological developments and consumer behavioral dynamics. The epidemiological burden of conventional alcohol consumption is examined alongside the physiological rationale supporting the widely adopted 0.5% alcohol by volume (ABV) threshold. Furthermore, global regulatory fragmentations, such as strict UK labeling laws versus broader EU and US standards, are highlighted as major sources of trade barriers and consumer confusion. From a technological standpoint, physical dealcoholization processes (including reverse osmosis, spinning cone columns, vacuum evaporation, and dialysis) and biological approaches (such as arrested fermentation and maltose-negative yeast strains) are critically evaluated across wine, beer and spirit-free matrices. Focus is directed toward formulation challenges aimed at mitigating sensory deficits, including texture restoration using hydrocolloids, sweetness management and the replication of ethanol-induced trigeminal burn through pungent compounds. Finally, the public health debate surrounding substitution versus addition effects of NoLo products is addressed, alongside the risks associated with “alibi marketing,” concluding with the outline of future research priorities encompassing longitudinal epidemiological monitoring, neurochemical priming mechanisms and legal framework harmonization.